• 1. Enabling stable MnO2 matrix for aqueous zinc-ion battery cathodes?
  Yiding Jiao,Liqun Kang,Jasper Berry-Gair,Kit McColl,Jianwei Li,Haobo Dong,Hao Jiang,Ryan Wang,Furio Corà,Dan J. L. Brett,Ivan P. Parkin J. Mater. Chem. A, 2020,8, 22075-22082
• 2. Fe(ii)-Assisted one-pot synthesis of ultra-small core–shell Au–Pt nanoparticles as superior catalysts towards the HER and ORR?
  Yi Cao,Yujiao Xiahou,Lixiang Xing,Xiang Zhang,Hong Li,ChenShou Wu,Haibing Xia Nanoscale, 2020,12, 20456-20466
• 3. Evidence of CO2 molecule acting as an electron acceptor on a nanoporous metal–organic-framework MIL-53 or Cr3+(OH)(O2C–C6H4–CO2)?
  Alexandre Vimont,Arnaud Travert,Philippe Bazin,Jean-Claude Lavalley,Marco Daturi,Christian Serre,Gérard Férey,Sandrine Bourrelly,Philip L. Llewellyn Chem. Commun., 2007, 3291-3293
• 4. Establishment and implications of a characterization method for magnetic nanoparticle using cell tracking velocimetry and magnetic susceptibility modified solutions
  Huading Zhang,Lee R. Moore,Maciej Zborowski,P. Stephen Williams,Shlomo Margel,Jeffrey J. Chalmers Analyst, 2005,130, 514-527
• 5. Excitation energies from ground-state density-functionals by means of generator coordinates
  A. B. F. da Silva,K. Capelle Phys. Chem. Chem. Phys., 2009,11, 4564-4569

Recent Advances in the Application of Ethyl 2-methylpyrimidine-5-carboxylate (CAS 2134-38-5) in Chemical Biology and Pharmaceutical Research

Ethyl 2-methylpyrimidine-5-carboxylate (CAS 2134-38-5) has emerged as a key building block in medicinal chemistry and drug discovery due to its versatile pyrimidine scaffold. Recent studies have highlighted its potential as a precursor for various bioactive compounds, particularly in the development of kinase inhibitors and antiviral agents. This research brief synthesizes the latest findings on this compound, focusing on its synthetic applications, biological activities, and therapeutic potential.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the compound's utility in synthesizing novel Bruton's tyrosine kinase (BTK) inhibitors. Researchers developed a series of derivatives through structural modifications at the 2-methyl and 5-carboxylate positions, yielding compounds with improved selectivity and potency against B-cell malignancies. The ethyl ester moiety (2134-38-5) proved crucial for maintaining optimal pharmacokinetic properties while allowing for efficient prodrug conversion in vivo.

In the field of antiviral research, Ethyl 2-methylpyrimidine-5-carboxylate has shown promise as a scaffold for RNA-dependent RNA polymerase inhibitors. A recent Nature Communications paper (2024) reported its incorporation into nucleotide analogs that effectively inhibited SARS-CoV-2 replication. The 2-methyl group was found to enhance membrane permeability, while the ester functionality facilitated intracellular activation of the prodrug form.

Significant progress has also been made in synthetic methodology development. A 2024 Organic Letters publication described a novel one-pot synthesis of Ethyl 2-methylpyrimidine-5-carboxylate from β-keto esters and amidines, achieving 85% yield under mild conditions. This improved synthetic route addresses previous challenges in large-scale production and has enabled more extensive structure-activity relationship studies.

The compound's role in chemical biology probes has expanded recently, with several studies utilizing it as a starting material for photoaffinity labeling agents and activity-based protein profiling reagents. Its balanced hydrophobicity and small molecular weight make it particularly suitable for developing cell-permeable probes that can target challenging protein classes.

Looking forward, Ethyl 2-methylpyrimidine-5-carboxylate continues to attract attention for its potential in targeted protein degradation strategies. Preliminary results from ongoing research suggest its derivatives may serve as effective E3 ligase-recruiting moieties in PROTAC designs, offering new opportunities for addressing previously undruggable targets in oncology and neurodegenerative diseases.

• 176240-74-7(5-Pyrimidinecarboxylicacid, 2-(1-methylethyl)-, methyl ester)
• 5571-03-9(5-Pyrimidinecarboxylic acid, 2-methyl-, methyl ester (7CI,8CI,9CI))
• 648423-77-2(Ethyl 2-Cyclopropylpyrimidine-5-carboxylate)
• 1788041-60-0(Methyl 2-(aminomethyl)pyrimidine-5-carboxylate hydrochloride)
• 5194-32-1(2-Methylpyrimidine-5-carboxylic acid)
• 34253-01-5(Methyl pyrimidine-5-carboxylate)
• 40929-50-8(Ethyl 5-pyrimidinecarboxylate)
• 944901-35-3(METHYL 2-(CHLOROMETHYL)PYRIMIDINE-5-CARBOXYLATE)
• 648423-76-1(5-Pyrimidinecarboxylic acid, 2-(1,1-dimethylethyl)-, ethyl ester)
• 139584-78-4(5-Pyrimidinecarboxylic acid, 2-propynyl ester)